Thus, despite the previous unsuccessful clinical trial of angiotensin receptor blockers in managing fibrosis in NAFLD patients [200], patients with the AGTR1 A1166C variant may exhibit a subtype of NAFLD that may benefit more from the personalized usage of angiotensin receptor blockers. Here, AGTR1 is linked to metabolic dysfunction-associated steatotic liver disease.